Collegium Pharmaceutical Q1 2026 slides: ADHD growth drives earnings beat

Collegium Pharmaceutical reported Q1 2026 product revenue of $193.5 million, beating consensus by 3.3%, while adjusted EBITDA rose 9% to $104 million and adjusted EPS of $1.76 topped estimates by nearly 8%. Management reiterated 2026 guidance for $805 million-$825 million in product sales and $455 million-$475 million in adjusted EBITDA, and detailed the pending $650 million AZSTARYS acquisition, which is expected to be immediately accretive and generate more than $50 million in second-half 2026 pro forma revenue. Shares were up 4.08% premarket to about $38 on the earnings beat and strategic deal.

Analysis

The market is likely underpricing the quality of the mix shift, not just the headline beat. COLL is moving from a single-product “opioid cash flow” story toward an ADHD platform with multiple commercial levers, which should compress the discount rate applied to the name because earnings become less binary and less exposed to payer/prescribing headwinds in one franchise. The real second-order winner is management’s capital allocation optionality: if AZSTARYS integrates smoothly, free cash flow can be recycled into buybacks or debt paydown faster than the market currently models, creating a self-funding growth loop.

The near-term setup is stronger than the medium-term setup. In the next 1–3 months, the stock can rerate on execution and guidance credibility, but after the acquisition closes, the burden shifts to integration, sales-force focus, and whether the ADHD portfolio can absorb incremental complexity without slowing Jornay’s momentum. The key risk is not revenue deterioration; it’s margin dilution from layering on a larger commercial footprint before synergies are visible, which can cap upside if investors start to value the deal as “financial engineering” rather than durable category expansion.

Consensus appears to be focusing on the acquisition’s accretion while missing the competitive response risk. A stronger COLL in ADHD could pressure smaller stimulant competitors and force more aggressive payer contracting, which may flatten category economics and slow share gains for the whole space. On the other hand, if AZSTARYS is more of a demand-recapture product than an expansion product, the upside is more limited than the market thinks; in that case the current move may already be pricing in a near-perfect integration path.

Key Decisions for Investors

• Long COLL on pullbacks over the next 1–2 weeks; use any post-open fade toward the high-$30s as entry, targeting a re-rating toward the low-to-mid $40s over 2–4 months if integration messaging stays clean.
• Buy COLL Jan-2027 calls and finance with a higher strike call sale to express medium-term upside with defined risk; thesis is multiple expansion if debt paydown and AZSTARYS synergies become visible by the next two quarters.
• Pair trade: long COLL / short a basket of smaller ADHD peers or single-product specialty pharma names over 3–6 months; COLL has the cleaner cash flow path and better capital return capacity, while peers face higher execution risk if stimulant competition intensifies.
• If already long, hedge event risk by trimming into strength ahead of the acquisition close; the trade-off is giving up some upside to avoid an integration reset that could hit the stock 10–15% if synergy timing slips.
• Watch for a confirmation signal: if management raises confidence on post-close synergy capture before the second-half print, add to longs; if adjusted margin stalls despite revenue growth, reduce exposure because the market will punish the 'growth at any cost' interpretation.